ABVC BioPharma, Inc.
ABVC
$2.41
-$0.12-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 22.67% | 40.58% | 196.13% | 72.18% | -10.73% |
| Total Other Revenue | 91.77% | 98.29% | 98.29% | 98.29% | -986.79% |
| Total Revenue | 56.53% | 186.88% | 1,901.57% | 234.16% | -31.04% |
| Cost of Revenue | -100.00% | -99.82% | -99.79% | -99.74% | -67.30% |
| Gross Profit | 115.73% | 1,292.07% | 334.43% | 440.17% | 18.94% |
| SG&A Expenses | 10.76% | -35.38% | -61.73% | -16.02% | -35.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 633.90% | 447.92% | 447.92% | 447.92% | -45.37% |
| Total Operating Expenses | 6.04% | -37.51% | -64.43% | -29.32% | -50.40% |
| Operating Income | -0.34% | 42.32% | 70.91% | 35.25% | 51.92% |
| Income Before Tax | 13.47% | 54.74% | 72.83% | 44.62% | 53.81% |
| Income Tax Expenses | -62.81% | -62.15% | -143.16% | -143.16% | -93.79% |
| Earnings from Continuing Operations | 14.09% | 54.80% | 74.76% | 47.67% | 57.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -47.51% | -34.48% | -21.94% | -20.52% | 424.95% |
| Net Income | 9.62% | 56.34% | 77.84% | 49.38% | 62.88% |
| EBIT | -0.34% | 42.32% | 70.91% | 35.25% | 51.92% |
| EBITDA | -0.33% | 42.54% | 71.31% | 35.45% | 52.10% |
| EPS Basic | 52.04% | 83.96% | 91.68% | 81.59% | 86.85% |
| Normalized Basic EPS | 45.70% | 85.55% | 92.84% | 81.74% | 88.87% |
| EPS Diluted | 52.18% | 84.00% | 91.70% | 81.62% | 86.82% |
| Normalized Diluted EPS | 45.70% | 85.55% | 92.84% | 81.74% | 88.87% |
| Average Basic Shares Outstanding | 71.44% | 82.34% | 118.28% | 169.00% | 187.16% |
| Average Diluted Shares Outstanding | 71.44% | 82.34% | 118.28% | 169.00% | 187.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |